RxDoctor Payments Data

Faddy Khamis, MD

Internal Medicine · Olathe, KSNPI 1891288338

Payments from drug & device makers

$335in general payments, 2019–2025

Across 20 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$140
  • Dexcom, Inc.$81
  • Lilly USA, LLC$24
  • Edwards Lifesciences$22
  • Neurocrine Biosciences, Inc.$21
  • La Jolla Pharmaceutical Company$16
  • plus $31 from 3 others

What the payments were for

  • Food & beverage$335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$335 in reported general payments places this provider in the 60th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$108,410
Medicare patients
433
Services billed
2,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide68$77,323
OzempicSemaglutide73$71,147
EliquisApixaban81$67,593
JardianceEmpagliflozin42$54,663
JanuviaSitagliptin Phosphate24$40,057
XareltoRivaroxaban30$31,379
RybelsusSemaglutide12$26,946
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$25,216
LinzessLinaclotide13$12,036
GemtesaVibegron28$11,412
FarxigaDapagliflozin Propanediol15$10,595
Tresiba Flextouch U-200Insulin Degludec17$10,554
NucyntaTapentadol Hcl12$10,466
Incruse ElliptaUmeclidinium Bromide22$9,857
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen264$5,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$140$98,09485 claims
Lilly USA, LLCMounjaro$24$77,32368 claims
Johnson & JohnsonXarelto$14$31,37930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →